Immunic 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vidofludimus (IMU-838) / Immunic
2021-000028-36: Not applicable

Not yet recruiting
3
1050
Europe, RoW
vidofludimus calcium, Vidofludimus calcium, IMU-838, Tablet
Immunic AG, Immunic AG
Relapsing Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-000029-28: Not applicable

Ongoing
3
1050
Europe
vidofludimus calcium, Vidofludimus calcium, IMU-838, Tablet
Immunic AG, Immunic AG
Relapsing Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
ENSURE-1, NCT05134441: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG
Multiple Sclerosis
09/24
09/32
ENSURE-2, NCT05201638: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, Vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG
Multiple Sclerosis, Relapsing-Remitting
10/24
10/32
2018-001895-39: A phase 2 Dose-finding study of IMU-838 in patients with active Crohn’s disease

Ongoing
2
258
RoW, Europe
vidofludimus calcium, IMU-838, Tablet
Immunic AG, Immunic AG
Crohn’s disease (CD), Crohn’s disease (CD), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
 
 
EMPhASIS, NCT03846219 / 2018-001896-19: MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis

Active, not recruiting
2
210
Europe, RoW
IMU-838 (30 mg/day), Vidofludimus Calcium, Oral Tablet (30 mg/day), IMU-838 (45 mg/day), Vidofludimus Calcium, Oral Tablet (45 mg/day), Placebo, IMU-838 (10 mg/day), Vidofludimus Calcium, Oral Tablet (10 mg/day)
Immunic AG
Relapsing-Remitting Multiple Sclerosis (RRMS)
04/20
12/29
IONIC, NCT04516915 / 2020-001805-21: IMU-838 and Oseltamivir in the Treatment of COVID-19

Completed
2
38
Europe
IMU-838, Intervention Arm, Oseltamivir, Control arm
University Hospitals Coventry and Warwickshire NHS Trust, Immunic AG, University of Warwick, MODEPHARMA
Covid 19
05/22
09/22
CALDOSE-1, NCT03341962 / 2017-003703-22: Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Hourglass Oct 2021 - Dec 2021 : Top-line data from CALDOSE-1 study in moderate-to-severe ulcerative colitis
Terminated
2
263
Europe, US, RoW
IMU-838, IM90838, vidofludimus calcium, Placebo, Placebo (for IMU-838)
Immunic AG
Ulcerative Colitis
11/22
11/22
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruiting
2
450
Europe, Canada, US, RoW
IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm
Immunic AG
Multiple Sclerosis
01/25
01/25
IMU-856 / Immunic
ACTRN12620000901909: A three-part, double-blind, placebo-controlled, Phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-856 in healthy volunteers and patients with Celiac disease

Completed
1
120
 
Immunic Australia Pty Ltd, Immunic Australia Pty Ltd
Diarrhea-predominant irritable bowel syndrome, Celiac disease
 
 
izumerogant (IMU-935) / Immunic
ACTRN12619001544167: A three-part, double-blind, placebo-controlled, phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-935 in healthy volunteers and Psoriasis Patients.

Completed
1
144
 
Immunic Australia Pty Ltd, Immunic Australia Pty Ltd
Psoriasis
 
 
NCT05124795: IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Terminated
1
18
Europe
IMU-935
Immunic AG
Metastatic Castration Resistant Prostate Cancer
05/23
05/23

Download Options